Hansa Biopharma AB Sweden

Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain           Encouraging results from first-in-human trial of HNSA-5487           Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta's SRP-9001 in DMDView original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-year-end-report-january-december-2023-302051738.html